Candel Therapeutics Inc (NASDAQ:CADL) Chief Scientific Officer Francesca Barone will present and join panels at the 7th Annual Glioblastoma Drug Development Summit in Boston on Feb. 17-19, 2026.
Barone will highlight data from Candel’s HSV-based platform and its CAN-3110 program in recurrent high-grade glioma, focusing on biomarker-driven development, patient stratification, imaging and biomarker integration, and biomarker-based enrollment in GBM trials.